Picton Mahoney Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Picton Mahoney Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300,000	Closed	-$5.27M	–	1117
2021 Q3	$5.27M	Buy	+300,000	New	+$3.5M	0.19%	114

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Picton Mahoney Asset Management's TRIL Position: Q4 2021 in Review

Picton Mahoney Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 300,000 shares — an estimated $5.27M sold.

Picton Mahoney Asset Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $5.27M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Picton Mahoney Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Picton Mahoney Asset Management sold 300,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.27M.
Picton Mahoney Asset Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Picton Mahoney Asset Management's Trillium Therapeutics Inc. position peaked at $5.27M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.